15 results on '"Enama, Mary E."'
Search Results
2. A West Nile Virus DNA Vaccine Utilizing a Modified Promoter Induces Neutralizing Antibody in Younger and Older Healthy Adults in a Phase I Clinical Trial
- Author
-
Ledgerwood, Julie E., Pierson, Theodore C., Hubka, Sarah A., Desai, Niraj, Rucker, Steve, Gordon, Ingelise J., Enama, Mary E., Nelson, Steevenson, Nason, Martha, Gu, Wenjuan, Bundrant, Nikkida, Koup, Richard A., Bailer, Robert T., Mascola, John R., Nabel, Gary J., and Graham, Barney S.
- Published
- 2011
- Full Text
- View/download PDF
3. A West Nile Virus DNA Vaccine Induces Neutralizing Antibody in Healthy Adults during a Phase 1 Clinical Trial
- Author
-
Vaccine Research Center 302 Study Team, Martin, Julie E., Pierson, Theodore C., Hubka, Sarah, Rucker, Steve, Gordon, Ingelise J., Enama, Mary E., Andrews, Charla A., Xu, Qing, Davis, Brent S., Nason, Martha C., Fay, Michael P., Koup, Richard A., Roederer, Mario, Bailer, Robert T., Gomez, Phillip L., Mascola, John R., Chang, Gwong-Jen J., Nabel, Gary J., and Graham, Barney S.
- Published
- 2007
- Full Text
- View/download PDF
4. Safety and immunogenicity of investigational seasonal influenza hemagglutinin DNA vaccine followed by trivalent inactivated vaccine administered intradermally or intramuscularly in healthy adults: An open-label randomized phase 1 clinical trial.
- Author
-
Carter, Cristina, Houser, Katherine V., Yamshchikov, Galina V., Bellamy, Abbie R., May, Jeanine, Enama, Mary E., Sarwar, Uzma, Larkin, Brenda, Bailer, Robert T., Koup, Richard, Chen, Grace L., Patel, Shital M., Winokur, Patricia, Belshe, Robert, Dekker, Cornelia L., Graham, Barney S., Ledgerwood, Julie E., and null, null
- Subjects
DNA vaccines ,SEASONAL influenza ,VACCINES ,CLINICAL trials ,INFLUENZA vaccines - Abstract
Background: Seasonal influenza results in significant morbidity and mortality worldwide, but the currently licensed inactivated vaccines generally have low vaccine efficacies and could be improved. In this phase 1 clinical trial, we compared seasonal influenza vaccine regimens with different priming strategies, prime-boost intervals, and administration routes to determine the impact of these variables on the resulting antibody response. Methods: Between August 17, 2012 and January 25, 2013, four sites enrolled healthy adults 18–70 years of age. Subjects were randomized to receive one of the following vaccination regimens: trivalent hemagglutinin (HA) DNA prime followed by trivalent inactivated influenza vaccine (IIV3) boost with a 3.5 month interval (DNA-IIV3), IIV3 prime followed by IIV3 boost with a 10 month interval (IIV3-IIV3), or concurrent DNA and IIV3 prime followed by IIV3 boost with a 10 month interval (DNA/IIV3-IIV3). Each regimen was additionally stratified by an IIV3 administration route of either intramuscular (IM) or intradermal (ID). DNA vaccines were administered by a needle-free jet injector (Biojector). Study objectives included evaluating the safety and tolerability of each regimen and measuring the antibody response by hemagglutination inhibition (HAI). Results: Three hundred and sixteen subjects enrolled. Local reactogenicity was mild to moderate in severity, with higher frequencies recorded following DNA vaccine administered by Biojector compared to IIV3 by either route (p <0.02 for pain, swelling, and redness) and following IIV3 by ID route compared to IM route (p <0.001 for swelling and redness). Systemic reactogenicity was similar between regimens. Though no overall differences were observed between regimens, the highest titers post boost were observed in the DNA-IIV3 group by ID route and in the IIV3-IIV3 group by IM route. Conclusions: All vaccination regimens were found to be safe and tolerable. While there were no overall differences between regimens, the DNA-IIV3 group by ID route, and the IIV3-IIV3 group by IM route, showed higher responses compared to the other same-route regimens. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
5. DNA vaccine priming for seasonal influenza vaccine in children and adolescents 6 to 17 years of age: A phase 1 randomized clinical trial.
- Author
-
Houser, Katherine V., Yamshchikov, Galina V., Bellamy, Abbie R., May, Jeanine, Enama, Mary E., Sarwar, Uzma, Larkin, Brenda, Bailer, Robert T., Koup, Richard, Paskel, Myeisha, Subbarao, Kanta, Anderson, Edwin, Bernstein, David I., Creech, Buddy, Keyserling, Harry, Spearman, Paul, Wright, Peter F., Graham, Barney S., Ledgerwood, Julie E., and null, null
- Subjects
DNA vaccines ,DNA primers ,COMMUNICABLE diseases ,IMMUNE response ,PEDIATRICS - Abstract
Background: Children are susceptible to severe influenza infections and facilitate community transmission. One potential strategy to improve vaccine immunogenicity in children against seasonal influenza involves a trivalent hemagglutinin DNA prime-trivalent inactivated influenza vaccine (IIV3) boost regimen. Methods: Sites enrolled adolescents, followed by younger children, to receive DNA prime (1 mg or 4 mg) intramuscularly by needle-free jet injector (Biojector), followed by split virus 2012/13 seasonal IIV3 boost by needle and syringe approximately 18 weeks later. A comparator group received IIV3 prime and boost at similar intervals. Primary study objectives included evaluation of the safety and tolerability of the vaccine regimens, with secondary objectives of measuring antibody responses at four weeks post boost by hemagglutination inhibition (HAI) and neutralization assays. Results: Seventy-five children ≥6 to ≤17 years old enrolled. Local reactogenicity was higher after DNA prime compared to IIV3 prime (p<0.001 for pain/tenderness, redness, or swelling), but symptoms were mild to moderate in severity. Systemic reactogenicity was similar between vaccines. Overall, antibody responses were similar among groups, although HAI antibodies revealed a trend towards higher responses following 4 mg DNA-IIV3 compared to IIV3-IIV3. The fold increase of HAI antibodies to A/California/07/2009 [A(H1N1)pdm09] was significantly greater following 4 mg DNA-IIV3 (10.12 fold, 5.60–18.27 95%CI) compared to IIV3-IIV3 (3.86 fold, 2.32–6.44 95%CI). Similar neutralizing titers were observed between regimens, with a trend towards increased response frequencies in 4 mg DNA-IIV3. However, significant differences in fold increase, reported as geometric mean fold ratios, were detected against the H1N1 viruses within the neutralization panel: A/New Caledonia/20/1999 (1.41 fold, 1.10–1.81 95%CI) and A/South Carolina/1/1918 (1.55 fold, 1.27–1.89 95%CI). Conclusions: In this first pediatric DNA vaccine study conducted in the U.S., the DNA prime-IIV3 boost regimen was safe and well tolerated. In children, the 4 mg DNA-IIV3 regimen resulted in antibody responses comparable to the IIV3-IIV3 regimen. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
6. DNA Priming for Seasonal Influenza Vaccine: A Phase 1b Double-Blind Randomized Clinical Trial.
- Author
-
Ledgerwood, Julie E., Bellamy, Abbie R., Belshe, Robert, Bernstein, David I., Edupuganti, Srilatha, Patel, Shital M., Renehan, Phyllis, Zajdowicz, Thad, Schwartz, Richard, Koup, Richard, Bailer, Robert T., Yamshchikov, Galina V., Enama, Mary E., Sarwar, Uzma, Larkin, Brenda, Graham, Barney S., and null, null
- Subjects
DNA primers ,SEASONAL influenza ,INFLUENZA vaccines ,VACCINE effectiveness ,DNA vaccines ,RANDOMIZED controlled trials - Abstract
Background: The efficacy of current influenza vaccines is limited in vulnerable populations. DNA vaccines can be produced rapidly, and may offer a potential strategy to improve vaccine immunogenicity, indicated by studies with H5 influenza DNA vaccine prime followed by inactivated vaccine boost. Methods: Four sites enrolled healthy adults, randomized to receive 2011/12 seasonal influenza DNA vaccine prime (n=65) or phosphate buffered saline (PBS) (n=66) administered intramuscularly with Biojector. All subjects received the 2012/13 seasonal inactivated influenza vaccine, trivalent (IIV3) 36 weeks after the priming injection. Vaccine safety and tolerability was the primary objective and measurement of antibody response by hemagglutination inhibition (HAI) was the secondary objective. Results: The DNA vaccine prime-IIV3 boost regimen was safe and well tolerated. Significant differences in HAI responses between the DNA vaccine prime and the PBS prime groups were not detected in this study. Conclusion: While DNA priming significantly improved the response to a conventional monovalent H5 vaccine in a previous study, it was not effective in adults using seasonal influenza strains, possibly due to pre-existing immunity to the prime, unmatched prime and boost antigens, or the lengthy 36 week boost interval. Careful optimization of the DNA prime-IIV3 boost regimen as related to antigen matching, interval between vaccinations, and pre-existing immune responses to influenza is likely to be needed in further evaluations of this vaccine strategy. In particular, testing this concept in younger age groups with less prior exposure to seasonal influenza strains may be informative. Trial Registration: ClinicalTrials.gov [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
7. Phase 1 Study of Pandemic H1 DNA Vaccine in Healthy Adults.
- Author
-
Crank, Michelle C., Gordon, Ingelise J., Yamshchikov, Galina V., Sitar, Sandra, Hu, Zonghui, Enama, Mary E., Holman, LaSonji A., Bailer, Robert T., Pearce, Melissa B., Koup, Richard A., Mascola, John R., Nabel, Gary J., Tumpey, Terrence M., Schwartz, Richard M., Graham, Barney S., Ledgerwood, Julie E., and null, null
- Subjects
INFLUENZA A virus, H1N1 subtype ,PANDEMICS ,DNA vaccines ,CLINICAL trials - Abstract
Background: A novel, swine-origin influenza A (H1N1) virus was detected worldwide in April 2009, and the World Health Organization (WHO) declared a global pandemic that June. DNA vaccine priming improves responses to inactivated influenza vaccines. We describe the rapid production and clinical evaluation of a DNA vaccine encoding the hemagglutinin protein of the 2009 pandemic A/California/04/2009(H1N1) influenza virus, accomplished nearly two months faster than production of A/California/07/2009(H1N1) licensed monovalent inactivated vaccine (MIV). Methods: 20 subjects received three H1 DNA vaccinations (4 mg intramuscularly with Biojector) at 4-week intervals. Eighteen subjects received an optional boost when the licensed H1N1 MIV became available. The interval between the third H1 DNA injection and MIV boost was 3–17 weeks. Vaccine safety was assessed by clinical observation, laboratory parameters, and 7-day solicited reactogenicity. Antibody responses were assessed by ELISA, HAI and neutralization assays, and T cell responses by ELISpot and flow cytometry. Results: Vaccinations were safe and well-tolerated. As evaluated by HAI, 6/20 developed positive responses at 4 weeks after third DNA injection and 13/18 at 4 weeks after MIV boost. Similar results were detected in neutralization assays. T cell responses were detected after DNA and MIV. The antibody responses were significantly amplified by the MIV boost, however, the boost did not increased T cell responses induced by DNA vaccine. Conclusions: H1 DNA vaccine was produced quickly, was well-tolerated, and had modest immunogenicity as a single agent. Other HA DNA prime-MIV boost regimens utilizing one DNA prime vaccination and longer boost intervals have shown significant immunogenicity. Rapid and large-scale production of HA DNA vaccines has the potential to contribute to an efficient response against future influenza pandemics. Trial Registration: Clinicaltrials.gov [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
8. DNA Vaccine Delivered by a Needle-Free Injection Device Improves Potency of Priming for Antibody and CD8+ T-Cell Responses after rAd5 Boost in a Randomized Clinical Trial.
- Author
-
Graham, Barney S., Enama, Mary E., Nason, Martha C., Gordon, Ingelise J., Peel, Sheila A., Ledgerwood, Julie E., Plummer, Sarah A., Mascola, John R., Bailer, Robert T., Roederer, Mario, Koup, Richard A., and Nabel, Gary J.
- Subjects
- *
DNA vaccines , *DRUG synergism , *IMMUNOGLOBULINS , *T cells , *CLINICAL trials , *DRUG delivery systems , *SYRINGES , *HYPODERMIC needles , *FOLLOW-up studies (Medicine) - Abstract
Background: DNA vaccine immunogenicity has been limited by inefficient delivery. Needle-free delivery of DNA using a CO2-powered Biojector® device was compared to delivery by needle and syringe and evaluated for safety and immunogenicity. Methods: Forty adults, 18–50 years, were randomly assigned to intramuscular (IM) vaccinations with DNA vaccine, VRC-HIVDNA016-00-VP, (weeks 0, 4, 8) by Biojector® 2000™ or needle and syringe (N/S) and boosted IM at week 24 with VRC-HIVADV014-00-VP (rAd5) with N/S at 1010 or 1011 particle units (PU). Equal numbers per assigned schedule had low (≤500) or high (>500) reciprocal titers of preexisting Ad5 neutralizing antibody. Results: 120 DNA and 39 rAd5 injections were given; 36 subjects completed follow-up research sample collections. IFN-γ ELISpot response rates were 17/19 (89%) for Biojector® and 13/17 (76%) for N/S delivery at Week 28 (4 weeks post rAd5 boost). The magnitude of ELISpot response was about 3-fold higher in Biojector® compared to N/S groups. Similar effects on response rates and magnitude were observed for CD8+, but not CD4+ T-cell responses by ICS. Env-specific antibody responses were about 10-fold higher in Biojector-primed subjects. Conclusions: DNA vaccination by Biojector® was well-tolerated and compared to needle injection, primed for greater IFN-γ ELISpot, CD8+ T-cell, and antibody responses after rAd5 boosting. Trial Registration: ClinicalTrials.gov NCT00109629 [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
9. Priming Immunization with DNA Augments Immunogenicity of Recombinant Adenoviral Vectors for Both HIV-1 Specific Antibody and T-Cell Responses.
- Author
-
Koup, Richard A., Roederer, Mario, Lamoreaux, Laurie, Fischer, Jennifer, Novik, Laura, Nason, Martha C., Larkin, Brenda D., Enama, Mary E., Ledgerwood, Julie E., Bailer, Robert T., Mascola, John R., Nabel, Gary J., and Graham, Barney S.
- Subjects
VACCINATION ,LYMPHOCYTES ,T cells ,VACCINES ,DNA vaccines ,IMMUNITY ,ENZYME-linked immunosorbent assay ,AIDS vaccines ,EPITOPES - Abstract
Background: Induction of HIV-1-specific T-cell responses relevant to diverse subtypes is a major goal of HIV vaccine development. Prime-boost regimens using heterologous gene-based vaccine vectors have induced potent, polyfunctional T cell responses in preclinical studies. Methods: The first opportunity to evaluate the immunogenicity of DNA priming followed by recombinant adenovirus serotype 5 (rAd5) boosting was as open-label rollover trials in subjects who had been enrolled in prior studies of HIV-1 specific DNA vaccines. All subjects underwent apheresis before and after rAd5 boosting to characterize in depth the T cell and antibody response induced by the heterologous DNA/rAd5 prime-boost combination. Results: rAd5 boosting was well-tolerated with no serious adverse events. Compared to DNA or rAd5 vaccine alone, sequential DNA/rAd5 administration induced 7-fold higher magnitude Env-biased HIV-1-specific CD8
+ T-cell responses and 100-fold greater antibody titers measured by ELISA. There was no significant neutralizing antibody activity against primary isolates. Vaccine-elicited CD4+ and CD8+ T-cells expressed multiple functions and were predominantly long-term (CD127+ ) central or effector memory T cells and that persisted in blood for >6 months. Epitopes mapped in Gag and Env demonstrated partial cross-clade recognition. Conclusion: Heterologous prime-boost using vector-based gene delivery of vaccine antigens is a potent immunization strategy for inducing both antibody and T-cell responses. Trial Registration: ClinicalTrails.gov NCT00102089, NCT00108654 [ABSTRACT FROM AUTHOR]- Published
- 2010
- Full Text
- View/download PDF
10. A West Nile Virus DNA Vaccine Induces Neutralizing Antibody in Healthy Adults during a Phase 1 Clinical Trial.
- Author
-
Martin, Julie E., Pierson, Theodore C., Hubka, Sarah, Rucker, Steve, Gordon, Ingelise J., Enama, Mary E., Andrews, Charla A., Qing Xu, Davis, Brent S., Nason, Martha C., Fay, Michael P., Koup, Richard A., Roederer, Mario, Bailer, Robert T., Gomez, Phillip L., Mascola, John R., Chang, Gwong-Jen J., Nabel, Gary J., and Graham, Barney S.
- Subjects
WEST Nile virus ,PREVENTIVE medicine ,DNA vaccines ,NEISSERIA meningitidis ,NEISSERIA ,IMMUNIZATION ,ENZYMES ,CATALYSTS ,FLAVIVIRUSES - Abstract
Background. West Nile virus (WNV) is a mosquitoborne flavivirus that can cause severe meningitis and encephalitis in infected individuals. We report the safety and immunogenicity of a WNV DNA vaccine in its first phase 1 human study. Methods. A single-plasmid DNA vaccine encoding the premembrane and the envelope glycoproteins of the NY99 strain of WNV was evaluated in an open-label study in 15 healthy adults. Twelve subjects completed the 3-dose vaccination schedule, and all subjects completed 32 weeks of evaluation for safety and immunogenicity. The development of a vaccine-induced immune response was assessed by enzyme-linked immunosorbant assay, neutralization assays, intracelluar cytokine staining, and enzyme-linked immunospot assay. Results. The vaccine was safe and well tolerated, with no significant adverse events. Vaccine-induced T cell and antibody responses were detected in the majority of subjects. Neutralizing antibody to WNV was detected in all subjects who completed the 3-dose vaccination schedule, at levels shown to be protective in studies of horses, an incidental natural host for WNV. Conclusions. Further assessment of this DNA platform for human immunization against WNV is warranted. Trial registration. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
11. An avian influenza H7 DNA priming vaccine is safe and immunogenic in a randomized phase I clinical trial.
- Author
-
DeZure, Adam D., Coates, Emily E., Hu, Zonghui, Yamshchikov, Galina V., Zephir, Kathryn L., Enama, Mary E., Plummer, Sarah H., Gordon, Ingelise J., Kaltovich, Florence, Andrews, Sarah, McDermott, Adrian, Crank, Michelle C., Koup, Richard A, Schwartz, Richard M., Bailer, Robert T., Sun, Xiangjie, Mascola, John R., Tumpey, Terrence M., Graham, Barney S., and Ledgerwood, Julie E.
- Subjects
H7N9 Influenza ,DNA vaccines ,CLINICAL trials ,INFLUENZA A virus, H5N1 subtype ,AVIAN influenza treatment - Abstract
A novel avian influenza subtype, A/H7N9, emerged in 2013 and represents a public health threat with pandemic potential. We have previously shown that DNA vaccine priming increases the magnitude and quality of antibody responses to H5N1 monovalent inactivated boost. We now report the safety and immunogenicity of a H7 DNA-H7N9 monovalent inactivated vaccine prime-boost regimen. In this Phase 1, open label, randomized clinical trial, we evaluated three H7N9 vaccination regimens in healthy adults, with a prime-boost interval of 16 weeks. Group 1 received H7 DNA vaccine prime and H7N9 monovalent inactivated vaccine boost. Group 2 received H7 DNA and H7N9 monovalent inactivated vaccine as a prime and H7N9 monovalent inactivated vaccine as a boost. Group 3 received H7N9 monovalent inactivated vaccine in a homologous prime-boost regimen. Overall, 30 individuals between 20 to 60 years old enrolled and 28 completed both vaccinations. All injections were well tolerated with no serious adverse events. 2 weeks post-boost, 50% of Group 1 and 33% of Group 2 achieved a HAI titer ≥1:40 compared with 11% of Group 3. Also, at least a fourfold increase in neutralizing antibody responses was seen in 90% of Group 1, 100% of Group 2, and 78% of Group 3 subjects. Peak neutralizing antibody geometric mean titers were significantly greater for Group 1 (GMT = 440.61, p < 0.05) and Group 2 (GMT = 331, p = 0.02) when compared with Group 3 (GMT = 86.11). A novel H7 DNA vaccine was safe, well-tolerated, and immunogenic when boosted with H7N9 monovalent inactivated vaccine, while priming for higher HAI and neutralizing antibody titers than H7N9 monovalent inactivated vaccine alone. Avian influenza: A vaccine for a deadly emergent strain A vaccine candidate to treat a deadly subtype of avian influenza was shown to induce protective antibodies in initial clinical trials. As of March 2017, avian influenza strain A/H7N9 has killed 497 people since 2013, with 1349 confirmed cases. Julie Ledgerwood and her team from the United States' National Institutes of Health in collaboration with colleagues at the Centers for Disease Control and Prevention tested their two-stage vaccine protocol in humans, showing it to be effective and safe. The vaccine consists of an initial injection of viral DNA, which 'primes' the immune system to the pathogen, followed by a follow-up injection of an inactivated purified viral protein, which further boosts the host's production of protective antibodies. The study shows the viability of this vaccine regimen and suggests further investigation into its appropriateness for treating avian influenza in humans. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
12. Phase I clinical evaluation of seasonal influenza hemagglutinin (HA) DNA vaccine prime followed by trivalent influenza inactivated vaccine (IIV3) boost.
- Author
-
Ledgerwood, Julie E., Hu, Zonghui, Costner, Pamela, Yamshchikov, Galina, Enama, Mary E., Plummer, Sarah, Hendel, Cynthia S., Holman, Lasonji, Larkin, Brenda, Gordon, Ingelise, Bailer, Robert T., Poretz, Donald M., Sarwar, Uzma, Kabadi, Alisha, Koup, Richard, Mascola, John R., and Graham, Barney S.
- Subjects
- *
SEASONAL influenza , *HEMAGGLUTININ , *IMMUNE response , *DNA vaccines , *IMMUNOGENETICS , *DNA primers , *PREVENTION - Abstract
Annual influenza vaccination reduces the risks of influenza when the vaccines are well matched to circulating strains, but development of an approach that induces broader and more durable immune responses would be beneficial. We conducted two companion Phase 1 studies, VRC 307 and VRC 309, over sequential seasons (2008–2009 and 2009–2010) in which only the influenza B strain component of the vaccines differed. Objectives were safety and immunogenicity of prime–boost vaccination schedules. A schedule of DNA vaccine encoding for seasonal influenza hemagglutinins (HA) prime followed by seasonal trivalent influenza inactivated vaccine (IIV3) boost (HA DNA–IIV3) was compared to placebo (PBS)–IIV3 or IIV3–IIV3. Cumulatively, 111 adults were randomized to HA DNA–IIV3 (n = 66), PBS–IIV3 (n = 25) or IIV3–IIV3 (n = 20). Safety was assessed by clinical observations, laboratory parameters and 7-day solicited reactogenicity. The seasonal HA DNA prime–IIV3 boost regimen was evaluated as safe and well tolerated. There were no serious adverse events. The local and systemic reactogenicity for HA DNA, IIV and placebo were reported predominantly as none or mild within the first 5 days post-vaccination. There was no significant difference in immunogenicity detected between the treatment groups as evaluated by hemagglutination inhibition (HAI) assay. The studies demonstrated the safety and immunogenicity of seasonal HA DNA–IIV3 regimen, but the 3–4 week prime–boost interval was suboptimal for improving influenza-specific immune responses. This is consistent with observations in avian H5 DNA vaccine prime–boost studies in which a long interval, but not a short interval, was associated with improved immunogenicity. Trial Registration: NCT00858611 for VRC 307 and NCT00995982 for VRC 309. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
13. A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial
- Author
-
Martin, Julie E., Louder, Mark K., Holman, LaSonji A., Gordon, Ingelise J., Enama, Mary E., Larkin, Brenda D., Andrews, Charla A., Vogel, Leatrice, Koup, Richard A., Roederer, Mario, Bailer, Robert T., Gomez, Phillip L., Nason, Martha, Mascola, John R., Nabel, Gary J., and Graham, Barney S.
- Subjects
- *
SARS disease , *DNA vaccines , *CORONAVIRUSES , *IMMUNOGLOBULINS , *CELLULAR immunity , *IMMUNE response , *COMMUNICABLE diseases , *CLINICAL trials , *VACCINATION - Abstract
Abstract: Background: The severe acute respiratory syndrome (SARS) virus is a member of the Coronaviridae (CoV) family that first appeared in the Guangdong Province of China in 2002 and was recognized as an emerging infectious disease in March 2003. Over 8000 cases and 900 deaths occurred during the epidemic. We report the safety and immunogenicity of a SARS DNA vaccine in a Phase I human study. Methods: A single-plasmid DNA vaccine encoding the Spike (S) glycoprotein was evaluated in 10 healthy adults. Nine subjects completed the 3 dose vaccination schedule and were evaluated for vaccine safety and immune responses. Immune response was assessed by intracellular cytokine staining (ICS), ELISpot, ELISA, and neutralization assays. Results: The vaccine was well tolerated. SARS-CoV-specific antibody was detected by ELISA in 8 of 10 subjects and neutralizing antibody was detected in all subjects who received 3 doses of vaccine. SARS-CoV-specific CD4+ T-cell responses were detected in all vaccinees, and CD8+ T-cell responses in ∼20% of individuals. Conclusions: The VRC SARS DNA vaccine was well tolerated and produced cellular immune responses and neutralizing antibody in healthy adults. [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
14. Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine
- Author
-
Catanzaro, Andrew T., Roederer, Mario, Koup, Richard A., Bailer, Robert T., Enama, Mary E., Nason, Martha C., Martin, Julie E., Rucker, Steve, Andrews, Charla A., Gomez, Phillip L., Mascola, John R., Nabel, Gary J., and Graham, Barney S.
- Subjects
- *
DNA vaccines , *HIV , *T cells , *VACCINATION - Abstract
Abstract: Needle-free delivery of a six-plasmid HIV-1 DNA vaccine encoding EnvA, EnvB, EnvC, and subtype B Gag, Pol, and Nef underwent open-label evaluation in 15 subjects; 14 completed the 0, 1, 2 month vaccination schedule. T cell responses to HIV-specific peptide pools were detected by intracellular cytokine staining of CD4+ [13/14 (93%)] and CD8+ [5/14 (36%)], and by ELISpot in 11/14 (79%). Ten of 14 (71%) had ELISA antibody responses to Env proteins. Compared to a four-plasmid product, Gag- and Nef-specific T cell responses were improved, while Env-specific responses were maintained. This candidate vaccine has now advanced to Phase II evaluation. [Copyright &y& Elsevier]
- Published
- 2007
- Full Text
- View/download PDF
15. Safety and Immunogenicityofa Gag-Pol Candidate HIV-1 DNA Vaccine Administered by a Needle-Free Device in HIV-1—Seronegative Subjects.
- Author
-
Tavel, Jorge A., Martin, Julie E., Kelly, Grace G., Enama, Mary E., Shen, Jean M., Gomez, Phillip L., Andrews, Charla A., Koup, Richard A., Bailer, Robert T., Stein, Judy A., Roederer, Mario, Nabel, Gary J., and Graham, Barney S.
- Subjects
- *
DNA vaccines , *HIV infections , *THERAPEUTICS , *T cells , *IMMUNOGLOBULINS , *DRUG delivery systems , *RESEARCH institutes - Abstract
The article evaluates the safety and immunogenicity of a Gag-Pol candidate HIV-1 DNA vaccine administered by a needle-free device in HIV-1-seronegative subjects. No HIV-specific antibody responses were detected, and only low-magnitude HIV-specific T cell responses were detected in eight of 15 vaccines. This initial product led to the development of a four-plasmid multiclade HIV DNA Vaccine Research Center vaccine candidate.
- Published
- 2007
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.